This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Zymeworks (ZYME) Stock Up 29% in Three Months: Here's Why
by Zacks Equity Research
Zymeworks (ZYME) recently entered a collaboration with Jazz Pharmaceuticals (JAZZ) for its lead pipeline candidate. This has been a significant catalyst for the stock.
Mesa Labs and Eldorado Gold have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Mesa Labs and Eldorado Gold are part of the Zacks Bull and Bear of the Day article.
Sanofi's (SNY) Dupixent & Vaccines Make the Stock Attractive
by Zacks Equity Research
One can invest in Sanofi (SNY) due to the strong performance of Dupixent, above-market sales growth of the Consumer unit, consistent pipeline innovation and regular accretive collaboration deals.
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying
by Sundeep Ganoria
We present three small biotech stocks, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2023 despite an uncertain macro environment.
Merck (MRK) Inks Deal to Develop Antibodies for Treating Cancer
by Zacks Equity Research
Merck (MRK) partners with Kelun-Biotech to develop seven antibody-drug conjugates targeting cancer indications. Merck will have an exclusive license to develop and commercialize these candidates.
Pfizer's (PFE) Etrasimod Filings Receive Review Acceptance
by Zacks Equity Research
The regulatory filings seek approval for Pfizer's (PFE) etrasimod in UC indication. A final decision in the U.S. is expected in 2023, while the decision in the EU is expected in 2024.
Zymeworks (ZYME) Up After Jazz Exercises Option for Cancer Drug
by Zacks Equity Research
Following positive data from a mid-stage study evaluating Zymeworks' (ZYME) lead candidate, Jazz (JAZZ) exercises its option to acquire the rights to develop and market this candidate.
Magenta (MGTA) Down on Pipeline Update for Leukemia Drug
by Zacks Equity Research
Magenta Therapeutics (MGTA) stops dosing participants in a phase I/II study cohort, evaluating its blood cancer pipeline candidate due to dose-limiting toxicities.
LianBio (LIAN) Up After Pfizer Opts in Rights to RSV Drug in China
by Zacks Equity Research
As a result of Pfizer's (PFE) opt-in for LianBio's (LIAN) rights to develop RSV therapeutic candidate sisunatovir in Greater China, the latter is eligible to receive potential royalties and milestone payments.
AstraZeneca (AZN) Gets EU Nod & CHMP Opinions for Some Drugs
by Zacks Equity Research
The CHMP recommends approvals for expanded use of AstraZeneca's (AZN) Enhertu in breast cancer, Imfinzi plus Imjudo in lung and liver cancers and Forxiga in heart failure.
Moderna's (MRNA) BA.1 Omicron Booster Gets CHMP Nod for Kids
by Zacks Equity Research
The CHMP recommends authorizing Moderna's (MRNA) bivalent COVID-19 booster vaccine, targeting the Omicron BA.1 subvariant, for young children aged between six and 11 years.
Wave Life Sciences (WVE) Up 26% on Collaboration With GSK
by Zacks Equity Research
Wave Lifesciences (WVE) signs a four-year research collaboration with GSK to advance discovery and development of oligonucleotide therapeutics focusing on novel genetic targets
Eli Lilly (LLY) 2023 Guidance Falls Short, Stock Declines
by Zacks Equity Research
Eli Lilly's (LLY) 2023 EPS guidance falls short of the Zacks Consensus Estimates and our model estimates. The company plans to launch four new drugs next year.
Moderna (MRNA) Up 20% on Upbeat Data From Cancer Jab Study
by Zacks Equity Research
Data from a mid-stage study showed that Moderna's (MRNA) personalized cancer vaccine candidate combined with Merck's Keytruda reduces the risk of recurrence/death by 44% in melanoma patients.
Vertex (VRTX) to Start Clinical Study on mRNA-based CF Therapy
by Zacks Equity Research
Following clearance of the IND application by the FDA, Vertex (VRTX) intends to start a clinical study evaluating a single ascending dose of VX-522 in cystic fibrosis patients in the coming weeks.
Alnylam (ALNY) Seeks to Expand Onpattro Label in Cardiomyopathy
by Zacks Equity Research
Alnylam (ALNY) initiates label expansion filing with FDA for Onpattro to treat cardiomyopathy in patients suffering from ATTR-amyloidosis. The drug is already approved to treat polyneuropathy in such patients.
Emergent (EBS) OTC Narcan Filing Gets FDA Priority Review Tag
by Zacks Equity Research
The FDA grants priority review to Emergent's regulatory filing seeking approval for an OTC version of its Narcan nasal spray. A final decision is expected by March 2023-end.
Oncolytics (ONCY) Up on Lead Drug Securing 2nd FDA Fast Track Tag
by Zacks Equity Research
Oncolytics Biotech (ONCY) receives a fast-track designation from the FDA for pelareorep combined with Roche's Tecentriq in advanced/metastatic pancreatic cancer indication.
Valneva (VALN) Up on 6-Month Lyme Disease Jab Persistence Data
by Zacks Equity Research
Persistence data from a mid-stage study showed that Valneva's (VALN) Lyme disease vaccine elicited antibody levels which remained above baseline six months after completing dose administration in children and adults.
New Strong Buy Stocks for November 28th
by Zacks Equity Research
KMDA, SLCA and FTNT have been added to the Zacks Rank #1 (Strong Buy) List on November 28, 2022.
Kamada (KMDA) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Kamada (KMDA) delivered earnings and revenue surprises of 433.33% and 8.26%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Aridis Pharmaceuticals (ARDS) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Aridis Pharmaceuticals (ARDS) delivered earnings and revenue surprises of -4,100% and 96.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Syros Pharmaceuticals, Inc. (SYRS) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 38.36% and 21.65%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Science 37 Holdings, Inc. (SNCE) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Science 37 Holdings, Inc. (SNCE) delivered earnings and revenue surprises of 5.88% and 21.12%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
IDEAYA Biosciences, Inc. (IDYA) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of 106.15% and 271.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?